Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07368283

Limited Target Volume Radiotherapy After Glioblastoma Surgery

Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity. Previous retrospective analysis by investigators revealed that local recurrences of glioblastoma are predominantly confined to a narrow margin around the original lesion: 98.3% of recurrences occurred within 0.5 cm of the original T2-FLAIR abnormality, 94.8% within 1 cm of the original T1-enhanced region. These findings have been cited in the ESTRO-EANO treatment guidelines. Building on this evidence, investigators plan to conduct a single-arm, phase II clinical trial to systematically evaluate the efficacy and safety of a 1 cm radiotherapy target volume in post-operative glioblastoma patients.Eligible patients with glioblastoma who have undergone surgical resection will be selected to receive limited-field radiotherapy. The target volume will be defined based on the postoperative MRI enhancing lesion: a 1 cm margin will be added to form the clinical target volume (CTV), followed by a further 0.3 cm margin to create the planning target volume (PTV). A total dose of 60 Gy will be delivered in 30 fractions (2 Gy per fraction, 5 fractions per week). Concurrent and adjuvant chemotherapy will be administered per standard guidelines. The primary efficacy endpoints are the 6-month progression-free survival rate and the incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher. Secondary endpoints include overall survival, patterns of recurrence, neurocognitive function, and quality of life.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Glioblastoma (GBM) Astrocytoma Glioblastoma Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 18 and 70 years.
  • Diagnosed with glioblastoma by surgical pathology, with the extent of resection achieving maximal safe resection.
  • Within 2 to 6 weeks after surgery
  • In good physical condition with a Karnofsky Performance Status (KPS) score ≥ 60.
  • Hematological, hepatic, and renal functions are essentially normal.
  • Signed informed consent, willing to undergo treatment and follow-up as stipulated in the study protocol.

Exclusion criteria

  • Prior history of cranial radiotherapy or other malignant tumors.
  • Severe dysfunction of vital organs (e.g., heart, liver, kidneys) that precludes tolerance to radiotherapy.
  • Active infection, immune system disorders, or other serious chronic diseases.
  • Pregnancy or lactation.
  • Psychiatric disorders or severe cognitive impairment that compromises the ability to cooperate with treatment and follow-up.

Treatment and study plan

limited-field radiotherapy

Radiation

limited-field radiotherapy + Concurrent and adjuvant TMZ chemotherapy

Primary outcomes

  1. 6m PFS

    Time frame: up to 6 month

    6-month progression-free survival rate

  2. incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher

    Time frame: Up to 24 months

Secondary outcomes

  1. OS

    Time frame: Up to 24 months

    overall survival

  2. Location of first recurrence relative to radiation field (in-field, marginal, or distant)

    Time frame: Up to 24 months

    The spatial relationship between the first documented site of disease recurrence/progression and the original radiation treatment plan will be determined by a core imaging laboratory. Recurrent lesions will be co-registered with the original planning CT/MRI and radiation dose distribution.

    Classification is based on the volume of the recurrent lesion covered by the 95% isodose line of the original prescription dose:

    In-field recurrence: >80% of the recurrent lesion's volume is within the 95% isodose line.

    Marginal recurrence: 20% to 80% of the recurrent lesion's volume is within the 95% isodose line.

    Distant recurrence: <20% of the recurrent lesion's volume is within the 95% isodose line.

    This classification criteria is adapted from the dosimetric analysis methods commonly used in radiotherapy studies (e.g., Patterns offailure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiation oncology 2014, 9:130.)

  3. Cognitive function assessed by Mini-Mental State Examination (MMSE) score

    Time frame: Up to 24 months

    Cognitive function assessed by the Mini-Mental State Examination (MMSE). Scores range from 0 to 30, with higher scores indicating better cognitive function.

  4. Cognitive function assessed by Montreal Cognitive Assessment (MoCA) score

    Time frame: Up to 24 months.

    Cognitive function assessed by the Montreal Cognitive Assessment (MoCA). Scores range from 0 to 30, with higher scores indicating better cognitive function.

  5. Health-Related Quality of Life as assessed by the EORTC QLQ-C30 Global Health Status / QoL scale

    Time frame: Up to 24 months

    Score on the Global Health Status / Quality of Life scale (Items 29 & 30) of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scale range: 0-100. A higher score indicates a better overall quality of life.

  6. Disease-Specific Quality of Life as assessed by the EORTC QLQ-BN20 summary score

    Time frame: Up to 24 months

    Summary score of the European Organization for Research and Treatment of Cancer Brain Cancer Module (EORTC QLQ-BN20). This scale assesses symptoms and issues specific to brain tumor patients (e.g., future uncertainty, visual disorder, motor dysfunction). Scale range and interpretation should be specified

  7. Quality of Life as assessed by the FACT-Br Total Score

    Time frame: Up to 24 months

    Total score of the Functional Assessment of Cancer Therapy - Brain (FACT-Br). This questionnaire assesses physical, social, emotional, functional well-being, and additional concerns specific to brain tumor patients. Scale range: 0-200. A higher score indicates better quality of life.

Study contacts

Contact information is provided by the study sponsor or research team.

Ziwei Tu

CONTACT

[email protected]

13755793552

Sponsors and collaborators

Lead sponsor

Jiangxi Provincial Cancer Hospital

Other

Registry information

Official study title

A Single-arm Phase II Non-inferiority Clinical Study of Limited Target Volume Radiotherapy After Glioblastoma Surgery

Important dates

Study start
2026
Primary completion
2028
Study completion
2030
First posted
Jan 26, 2026
Registry last updated
Jan 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.